110 related articles for article (PubMed ID: 31642110)
1. Circular RNA LARP4 correlates with decreased Enneking stage, better histological response, and prolonged survival profiles, and it elevates chemosensitivity to cisplatin and doxorubicin via sponging microRNA-424 in osteosarcoma.
Hu Y; Gu J; Shen H; Shao T; Li S; Wang W; Yu Z
J Clin Lab Anal; 2020 Feb; 34(2):e23045. PubMed ID: 31642110
[TBL] [Abstract][Full Text] [Related]
2. circ_0002060 Enhances Doxorubicin Resistance in Osteosarcoma by Regulating the miR-198/ABCB1 Axis.
Ji Y; Liu J; Zhu W; Ji J
Cancer Biother Radiopharm; 2023 Nov; 38(9):585-595. PubMed ID: 33351694
[No Abstract] [Full Text] [Related]
3. Biological functions of Circular RNA_LARP4/ Upstream frameshift 1 in development of gastric cancer.
Zhang J; Yang Y; Song X; Xing K; Chen Y
Cell Mol Biol (Noisy-le-grand); 2024 Apr; 70(4):176-180. PubMed ID: 38678610
[TBL] [Abstract][Full Text] [Related]
4. Alteration in the Expression of Circular Rnas and its association with the Development and Progression of Osteosarcoma, an Integrative Review with High Sensitivity Research.
Lima FA; Fernandes FL; Almeida DRQ; Carvalho AE; Almeida VD; Cavalcante GA; Morais NM; Rodrigues TD; Nascimento EGCD; Oliveira IT; Bezerra CM; Fernandes JV; Fernandes TTAAM
Asian Pac J Cancer Prev; 2024 Apr; 25(4):1195-1203. PubMed ID: 38679978
[TBL] [Abstract][Full Text] [Related]
5. A novel small-molecule antagonist enhances the sensitivity of osteosarcoma to cabozantinib in vitro and in vivo by targeting DNMT-1 correlated with disease severity in human patients.
Wang JH; Zeng Z; Sun J; Chen Y; Gao X
Pharmacol Res; 2021 Nov; 173():105869. PubMed ID: 34481973
[TBL] [Abstract][Full Text] [Related]
6. Negative Correlation Between Circular RNA SMARC5 and MicroRNA 432, and Their Clinical Implications in Bladder Cancer Patients.
Zhang Z; Sang Y; Liu Z; Shao J
Technol Cancer Res Treat; 2021; 20():15330338211039110. PubMed ID: 34482767
[No Abstract] [Full Text] [Related]
7. miR-1293 suppresses osteosarcoma progression by modulating drug sensitivity in response to cisplatin treatment.
Wang T; Huang J; Chen G; Fu J; Li T; Zou X; Yi H
Int Immunopharmacol; 2024 Mar; 130():111702. PubMed ID: 38367464
[TBL] [Abstract][Full Text] [Related]
8. Targeting CD44 by CRISPR-Cas9 in Multi-Drug Resistant Osteosarcoma Cells.
Xiao Z; Wan J; Nur AA; Dou P; Mankin H; Liu T; Ouyang Z
Cell Physiol Biochem; 2018; 51(4):1879-1893. PubMed ID: 30504723
[TBL] [Abstract][Full Text] [Related]
9. Prospective clinical trial testing COXEN-based gene expression models of chemosensitivity in dogs with spontaneous osteosarcoma.
Gustafson DL; Collins KP; Fowles JS; Ehrhart EJ; Weishaar KM; Das S; Duval DL; Thamm DH
Cancer Chemother Pharmacol; 2021 Oct; 88(4):699-712. PubMed ID: 34263337
[TBL] [Abstract][Full Text] [Related]
10. EFHD1 promotes osteosarcoma proliferation and drug resistance by inhibiting the opening of the mitochondrial membrane permeability transition pore (mPTP) by binding to ANT3.
Shen X; Ma M; Mi R; Zhuang J; Song Y; Yang W; Li H; Lu Y; Yang B; Liu Y; Wu Y; Shen H
Cell Mol Life Sci; 2024 May; 81(1):236. PubMed ID: 38795203
[TBL] [Abstract][Full Text] [Related]
11. Ascorbate sensitizes human osteosarcoma cells to the cytostatic effects of cisplatin.
Oka N; Komuro A; Amano H; Dash S; Honda M; Ota K; Nishimura S; Ueda T; Akagi M; Okada H
Pharmacol Res Perspect; 2020 Aug; 8(4):e00632. PubMed ID: 32725721
[TBL] [Abstract][Full Text] [Related]
12. The RNA-binding protein LARP4 regulates cancer cell migration and invasion.
Seetharaman S; Flemyng E; Shen J; Conte MR; Ridley AJ
Cytoskeleton (Hoboken); 2016 Nov; 73(11):680-690. PubMed ID: 27615744
[TBL] [Abstract][Full Text] [Related]
13. Loss of Runx2 sensitises osteosarcoma to chemotherapy-induced apoptosis.
Roos A; Satterfield L; Zhao S; Fuja D; Shuck R; Hicks MJ; Donehower LA; Yustein JT
Br J Cancer; 2015 Nov; 113(9):1289-97. PubMed ID: 26528706
[TBL] [Abstract][Full Text] [Related]
14. m
Zhang D; Guo Q; You K; Zhang Y; Zheng Y; Wei T
J Orthop Surg Res; 2024 Jan; 19(1):33. PubMed ID: 38178201
[TBL] [Abstract][Full Text] [Related]
15. The strategy and clinical relevance of in vitro models of MAP resistance in osteosarcoma: a systematic review.
Tippett VL; Tattersall L; Ab Latif NB; Shah KM; Lawson MA; Gartland A
Oncogene; 2023 Jan; 42(4):259-277. PubMed ID: 36434179
[TBL] [Abstract][Full Text] [Related]
16. Expression analysis of genes associated with human osteosarcoma tumors shows correlation of RUNX2 overexpression with poor response to chemotherapy.
Sadikovic B; Thorner P; Chilton-Macneill S; Martin JW; Cervigne NK; Squire J; Zielenska M
BMC Cancer; 2010 May; 10():202. PubMed ID: 20465837
[TBL] [Abstract][Full Text] [Related]
17. CPPs-modified chitosan as permeability-enhancing chemotherapeutic combined with gene therapy nanosystem by thermosensitive hydrogel for the treatment of osteosarcoma.
Cao J; Zhu C; Cao Z; Ke X
Int J Biol Macromol; 2024 May; 267(Pt 2):130915. PubMed ID: 38561118
[TBL] [Abstract][Full Text] [Related]
18. M
He M; Wang Y; Xie J; Pu J; Shen Z; Wang A; Li T; Wang T; Li G; Liu Y; Mei Z; Ren Z; Wang W; Liu X; Hong J; Liu Q; Lei H; He X; Du W; Yuan Y; Yang L
Oncogene; 2024 Jan; 43(5):341-353. PubMed ID: 38040806
[TBL] [Abstract][Full Text] [Related]
19. BRD4-targeting PROTACs Synergize With Chemotherapeutics Against Osteosarcoma Cell Lines.
Lang C; Stickler S; Rath B; Teufelsbauer M; Weigl L; Hohenegger M; Hamilton G
Anticancer Res; 2024 Mar; 44(3):971-980. PubMed ID: 38423674
[TBL] [Abstract][Full Text] [Related]
20. MicroRNA-mRNA networks define translatable molecular outcome phenotypes in osteosarcoma.
Lietz CE; Garbutt C; Barry WT; Deshpande V; Chen YL; Lozano-Calderon SA; Wang Y; Lawney B; Ebb D; Cote GM; Duan Z; Hornicek FJ; Choy E; Petur Nielsen G; Haibe-Kains B; Quackenbush J; Spentzos D
Sci Rep; 2020 Mar; 10(1):4409. PubMed ID: 32157112
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
